Poziotinib in Non–Small-Cell Lung Cancer Harboring HER2 Exon 20 Insertion Mutations After Prior Therapies: ZENITH20-2 Trial

Insertion mutations in Erb-b2 receptor tyrosine kinase 2 gene (ERBB2 or HER2) exon 20 occur in 2%-5% of non–small-cell lung cancers (NSCLCs) and function as an oncogenic driver. Poziotinib, a tyrosine kinase inhibitor, was evaluated in previously treated patients with NSCLC with HER2 exon 20 inserti...

Descripción completa

Detalles Bibliográficos
Autores principales: Le, Xiuning, Cornelissen, Robin, Garassino, Marina, Clarke, Jeffrey M., Tchekmedyian, Nishan, Goldman, Jonathan W., Leu, Szu-Yun, Bhat, Gajanan, Lebel, Francois, Heymach, John V., Socinski, Mark A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2022
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8887939/
https://www.ncbi.nlm.nih.gov/pubmed/34843401
http://dx.doi.org/10.1200/JCO.21.01323

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8887939/
https://www.ncbi.nlm.nih.gov/pubmed/34843401
http://dx.doi.org/10.1200/JCO.21.01323

Ejemplares similares